Pionyr Immunotherapeutics' Series B Round

Pionyr Immunotherapeutics raised a round of funding on December 13, 2017.

Pionyr, formerly Precision Immune, is developing cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity. The company is exploiting novel target discover…

Articles about Pionyr Immunotherapeutics' Series B Round: